Chris Rusconi Joins RefinedScience as Chief Scientific Officer

Chris brings exactly the kind of scientific leadership RefinedScience needs for this next stage of growth: rigorous, translational, and grounded in the practical realities of drug discovery and development.

Chris has built and led discovery and translational R&D organizations, advancing therapeutic programs from target discovery through preclinical development. He also brings board and advisory experience through Oak Bay Biosciences and the Emory Drug Development Fund, advising on R&D strategy, scientific due diligence, translational planning, and portfolio decisions.

At RefinedScience, Chris will help shape our scientific direction as we continue to grow our work across patient-linked human tissue, single-cell and spatial biology, functional validation, and clinically annotated multi-omics data.

Read more about Chris here.